Anders Rabbe, CEO, Isofol Medical discusses the developments of new therapies for patients with advanced colorectal cancer, a devastating disease with limited treatment options.\xa0 Isofol is developing arfolitixorin to increase the efficacy of standard of care chemotherapy and is actively enrolling patients in a global Phase 3 clinical trial.
#CRC #ColonCancer #ColorectalCancer #FightCRC #FightCancer